Purchase Order 75N91021P00789

The National Cancer Institute awarded a $22,622.75 firm fixed-price purchase order to Agilent Technologies Inc. on August 24, 2021, for the administrative de-obligation of unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), with an ultimate completion date of August 23, 2022. The contract was performed at Agilent's Customer Service and Sales division location in Marshallton, Delaware, and utilized no set-aside designation. This action represents a standard administrative closure mechanism enabling the National Cancer Institute to return unobligated balances to the Treasury prior to the September 30, 2026, expiration of fiscal year 2021 fund availability.

Agilent Technologies Inc., a global leader in advanced analytical instrumentation and laboratory services, maintains an extensive federal contract portfolio supporting scientific research and diagnostic operations across civilian and defense agencies. The company specializes in providing sophisticated equipment such as gas chromatography-mass spectrometry (GC-MS) systems, liquid chromatography-mass spectrometry (LC-MS) instruments, and inductively coupled plasma mass spectrometers (ICP-MS), along with comprehensive maintenance and repair services. Agilent holds significant long-term strategic relationships with federal agencies, including a $14.3 million indefinite delivery contract with the U.S. Army Research, Development and Engineering Command extending through January 2030, and a $325,000 blanket purchase agreement with the Department of Veterans Affairs, demonstrating its established positioning as a preferred vendor for critical laboratory infrastructure support.